You are here: Industry Insights > Migraine

News List

FDA approves novel preventive treatment for migraine worldpharmanews
June 05, 2018
The U.S. Food and Drug Administration today approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults.
Will Amgen’s migraine win and 5th thumbs-up for Prolia drive enough growth? Nope, says analyst fiercepharma
May 23, 2018
From the looks of it, Amgen is having a bang-up week.
FDA approves novel preventive treatment for migraine worldpharmanews
May 23, 2018
The U.S. Food and Drug Administration today approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults.
New Migraine Registry Offers Hope for Patients biospace
April 27, 2018
Patient registries can significantly advance the understanding and treatment of a particular disease
New migraine study reveals Alder drug’s treatment benefits biospectrumasia
April 26, 2018
The data are being presented at the American Academy of Neurology Annual Meeting in Los Angeles.
AOBiome Therapeutics Expands Clinical-Stage Pipeline, Initiates Phase 2 Clinical Trial for Episodic Migraine biospace
April 24, 2018
AOBiome Therapeutics announced today that AOBiome has conducted a randomized, double-blind, phase 2 study
How This Little Biopharma Could Beat Amgen, Teva to the Migraine Finish Line biospace
January 18, 2018
On Jan. 8, Alder BioPharmaceuticals announced that its eptinezumab met its primary endpoint in its Phase III PROMISE 2 clinical trial for preventing migraine.
Teva Sees Approval at Finish Line for Anti-CGRP Migraine Treatment biospace
December 25, 2017
With a priority review voucher in hand, Teva Pharmaceuticals is expecting the U.S. Food and Drug Administration to rule on its new migraine treatment fremanezumab by June.
Teva’s anti-CGRP drug under review for migraine pharmatimes
December 20, 2017
US regulators are now reviewing Teva Pharmaceutical’s experimental anti-CGRP therapy fremanezumab for the preventive treatment of migraine, and have also granted the drug a fast track designation for the prevention of cluster headache.
FDA Accepts BLA to Review Galcanezumab for Migraine americanpharmaceuticalreview
December 12, 2017
Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) to review galcanezumab for the prevention of migraine in adults

Previous page 1 2 3 4 5 6 7 8 9 Next page